Abstract:The growing use of molecular imaging helps to control and monitor dosage for increased safety and effectiveness. Molecular imaging agents become the scientific tools for moving a concept from bench work to clinic product development. This special issue provides original research and review of new trends in molecular imaging agent development. Among clinic molecular imaging modalities, radionuclide imaging technique is the most sensitive and could provide target-specific information. The radiotracer could non-invasively assess disease treatment endpoints which used to rely almost exclusively on biopsies and histopathological assays. L.-H. Shen et al. (Taiwan) reviewed molecular imaging in the diagnosis and management of CNS disorders. F.-L. Kong et al. (USA), N. Tsao et al. (USA), and C.-L. Ho et al. (Taiwan) report pharmacokinetics and dosimetry of molecular imaging compounds in oncology. M.-H. Liao et al. (Taiwan), X. Wang et al. (China), C. Wu et al. (China) and M. Tian et al. (USA) reported that molecular imaging techniques play a major role in the development of novel therapies since they measure target expressions (apoptosis, glycolysis) as well as function, pathway activities, and cell migration in the intact organism. Y.-F. Wang et al. and M.-Y. Chao et al. (Taiwan) described the kit probe for 99mTc-labeling which is crucial for centralized drug process. The kit probe may allow theranostic concept. A theranostic agent would be more accurate in the evaluation of patient response to treatment. The radiotracer could also be used for radionuclide therapy as reported by C. Wang et al. (China). Hybrid molecular imaging modalities (PET/CT, SPECT/CT) provide high-sensitivity functional and high-resolution anatomical imaging which are important in design-personalized treatment. M.-C. Chen et al. (Taiwan) reported the value of using I-131 NP-59 SPECT/CT to diagnose patients with subclinical or atypical features of primary aldosteronism. To proof of concept for molecular biology findings using different imaging modalities (optical, sonography) were described by Z. Pu et al. (China). In summary, molecular imaging enables the comprehensive characterization of therapeutic intervention and can be used in preclinical studies, pharmacokinetic studies, dose-finding studies, and proof-of-concept studies. Molecular imaging technologies promote the discovery and development of personalized medicine. Hong Zhang Mei Tian Carrio Ignasi Zhen Cheng Lie-Hang Shen David J. Yang

Nuclear medicine imaging in non-seminomatous germ cell tumors: lessons learned from the past failures

Targeted Nanobody-Based Molecular Tracers for Nuclear Imaging and Image-Guided Surgery

Nuclear Medicine and Molecular Imaging Applications in Gynecologic Malignancies: A Comprehensive Review

Nuclear medicine imaging for bone metastases assessment: what else besides bone scintigraphy in the era of personalized medicine?

Advancements in nuclear imaging using radiolabeled nanobody tracers to support cancer immunotherapy

Molecular Image-Guided Theranostic and Personalized Medicine 2013

Radiotracer Innovations in Breast Cancer Imaging: A Review of Recent Progress

Nuclear Medicine Imaging Techniques in Glioblastomas

Somatostatin Receptor-Based Molecular Imaging and Therapy for Neuroendocrine Tumors.

State-of-the-Art Hybrid Imaging of Neuroendocrine Neoplasms

Molecular imaging phenotyping for selecting and monitoring radioligand therapy of neuroendocrine neoplasms

Sentinel Node Imaging and Radioguided Surgery in the Era of SPECT/CT and PET/CT: Toward New Interventional Nuclear Medicine Strategies

Recent Advances in Molecular Image-Guided Cancer Radionuclide Therapy.

Recommendations for the use of nuclear medicine imaging in patients with neuroblastoma

Current status of contemporary diagnostic radiotracers in the management of breast cancer: first steps toward theranostic applications

Molecular Imaging and Therapy for Neuroendocrine Tumors

New Technologies for Human Cancer Imaging

Radiotheranostics - Precision Medicine in Nuclear Medicine and Molecular Imaging

Molecular imaging for non-invasive risk stratification of renal masses

Inspired by Novel Radiopharmaceuticals: Rush Hour of Nuclear Medicine.

Nuclear Medicine: the Synergy of Radiochemistry and Molecular Medicine